Investment in patient impact
Helping validated therapeutic innovations reach more patients.
Software & Solutions
Severan provides biopharma and medtech companies with tailored, non-dilutive financing to power commercialization — enabling innovations to reach patients faster and at greater scale.
Trusted by 500+ companies worldwide
Capital. Expertise. Commercialization.
Non-dilutive financing for biopharma and medtech, built around what comes after the science.
We provide structured, non-dilutive capital alongside commercial, scientific, and access expertise, so founders can accelerate adoption without giving up equity, IP, or control of their company's direction.
.svg)
Speed to patients
Accelerate the path from approval to patients
.svg)
Overlooked value
Surface value that generalist capital overlooks
.svg)
Commercial scale
Scale commercialization across therapeutics, diagnostics, and medical devices
.svg)
Expert underwriting
Underwritten by commercial, scientific, and market access experts
.svg)
Founder ownership
Preserve equity, IP, and strategic independence as you grow
Beyond the mainstream
Backed by rigorous diligence, including in therapeutic areas outside institutional focus
Intelligent solutions
Purpose-driven capital with measurable impact
Severan Capital originates revenue-based investments into biomedical innovations with high potential for patient impact.
Built on alignment
Severan investments strategically align innovators and investors, linking patient impact with financial returns:
Returns scale as products are adopted by doctors and patients
Financial performance reflects patient access, not corporate exits
No trade-off between patient impact and investor outcomes
Learn more
Learn more
Asset-backed structure
Secured against commercial assets, not equity or balance sheet.
.svg)
No maturity pressure
No fixed maturity date, no refinancing cliff.
.svg)
Covenant-light terms
Structured without covenants that constrain operations.
Exposure where it compounds
A differentiated entry point into life sciences — at the stage where science becomes scale.
Proven, not speculative
Asset-secured returns
Aligned outcomes
Learn more
Learn more
Raise Capital With Severan
Financing structured around your inflection point.
Severan partners with life sciences companies to design non-dilutive financings tailored to the moment — whether that's a commercial launch, a label expansion, or a pivotal scale-up.
Designed for the commercialization edge
Severan's financings are designed for innovators at the commercialization edge — where capital structure determines how fast a product reaches scale.
Late-clinical to commercial-stage biopharma, medtech, and diagnostics companies.
Companies with near-term or existing revenues and clear product-level cash flows
Management teams seeking non-dilutive growth capital without loss of strategic control
Learn more
Learn more
When is revenue financing is most attractive?
Pre- or post-launch inflection points (commercial build-out, market expansion, lifecycle investment)
When equity is expensive or highly dilutive due to valuation compression or market volatility
When traditional debt is constrained by covenants, amortization, or balance-sheet risk
Why revenue financing vs. equity and debt?
Preserves long-term equity upside while funding commercialization
Aligns capital repayment with product performance (sales-linked, not fixed)
Avoids governance dilution (no board seats, no control provisions)
Lower effective cost of capital than equity at comparable risk stages
Operationally flexible versus debt (minimal covenants)
Built by operators
A Team Purpose-Built to Underwrite Life Sciences Commercial Risk
Severan Capital was founded to create new pathways for investing in biomedical innovation, and to empower scientific innovators who want to grow without ceding strategic control. Our team is led by experienced operators across biopharma and medtech, with deep diligence rigor in the commercial dynamics that determine success — go-to-market strategy, competitive positioning, reimbursement risk, and policy evolution.
Max Hunt
Founder & CEO
Mia Thompson
Co-Founder & COO
Liam Becker
Lead Engineer
Emily Park
Product Designer
Noah Martinez
Software Engineer
Sophia Alvarez
Head of Operations
Questions & Answers
The Commercialization Capital Gap
Find clear, straightforward answers to the most common questions about our approach. Severan provides structured, non-dilutive capital to life sciences companies through synthetic capped royalty and revenue-based financing.
1. Why is there a financing gap in biomedical commercialization?
2. Where is the funding gap most persistent?
3. What is royalty financing?
4. What is synthetic capped royalty financing?
